Damora Therapeutics (DMRA) Income from Continuing Operations (2019 - 2026)
Damora Therapeutics (DMRA) reported Income from Continuing Operations of 27783000.0 for Q1 2026, down 996.84% on a YoY basis from 3097871.15 in Q1 2025, and up 85.89% quarter-over-quarter from 196876000.0 in Q4 2025.
Damora Therapeutics (DMRA) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Damora Therapeutics has reported Income from Continuing Operations for 8 years, with the latest figure at 27783000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 996.84% year-over-year to 27783000.0; the trailing twelve-month figure through Mar 2026 stood at 231229000.0 (down 3133.97% YoY), and the FY2025 full-year result was 205979000.0, down 1940.61% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 27783000.0, up from 196876000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4604000.0 in Q4 2024, with the low at 196876000.0 in Q4 2025.
- Historically, Income from Continuing Operations has averaged 20230000.0 across 5 years, with a median of 8136000.0 in 2023.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations soared 171.1% — and 2025, when it slumped 4376.19%.
- Damora Therapeutics' Income from Continuing Operations stood at 13525000.0 in 2022, then surged by 52.13% to 6475000.0 in 2023, then soared by 171.1% to 4604000.0 in 2024, then tumbled by 4376.19% to 196876000.0 in 2025, then soared by 85.89% to 27783000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 27783000.0 (Q1 2026), 196876000.0 (Q4 2025), and 3133000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Damora Therapeutics | 731.26 Mn | 528.86 Mn | - | -27.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.78 Mn |
| Dec 31, 2025 | -196.88 Mn |
| Sep 30, 2025 | -3.13 Mn |
| Jun 30, 2025 | -3.44 Mn |
| Mar 31, 2025 | -2.53 Mn |
| Dec 31, 2024 | 4.60 Mn |
| Sep 30, 2024 | -3.88 Mn |
| Jun 30, 2024 | -5.34 Mn |
| Mar 31, 2024 | -5.48 Mn |
| Dec 31, 2023 | -6.48 Mn |
| Sep 30, 2023 | -8.14 Mn |
| Jun 30, 2023 | -10.74 Mn |
| Mar 31, 2023 | -13.49 Mn |
| Dec 31, 2022 | -13.53 Mn |
| Sep 30, 2022 | -13.62 Mn |
| Jun 30, 2022 | -17.12 Mn |
| Mar 31, 2022 | -16.94 Mn |
| Dec 31, 2021 | -13.47 Mn |
| Sep 30, 2021 | -12.94 Mn |
| Jun 30, 2021 | -12.27 Mn |